NASDAQ:OPTN
OptiNose Inc. Stock News
$1.17
+0.0600 (+5.41%)
At Close: May 28, 2024
Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
09:26pm, Monday, 15'th Nov 2021 GlobeNewswire Inc.
Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020
Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
09:26pm, Monday, 15'th Nov 2021 Intrado Digital Media
Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020
OptiNose (OPTN) Reports Q3 Loss, Lags Revenue Estimates
08:47pm, Monday, 15'th Nov 2021
OptiNose (OPTN) delivered earnings and revenue surprises of 13.51% and -8.68%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Nasal Polyps Diagnosis and Treatment Market to eyewitness massive growth by 2027 | OptiNose US, Sanofi, Pfizer, Regeneron Pharmaceuticals, GlaxoSmithKline
09:36am, Monday, 15'th Nov 2021 Cheshire Media
Nasal Polyps Diagnosis and Treatment Market Scenario 2020-2027: The Global Nasal Polyps Diagnosis and Treatment market exhibits comprehensive information that is a valuable source of insightful data for business strategists during the decade 2014-2027. On the basis of historical data, Nasal Polyps Diagnosis and Treatment market report provides key segments and their sub-segments, revenue and []
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
02:57pm, Sunday, 14'th Nov 2021 Benzinga
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
Among the
Optinose Announces Reporting Date for Third Quarter 2021 Financial Results
05:50pm, Wednesday, 10'th Nov 2021
Conference Call and Webcast to be held November 16, 2021 at 8:30 a.m. Eastern Time
Optinose to Present at the Cantor Virtual Global Healthcare Conference
04:15pm, Wednesday, 22'nd Sep 2021
YARDLEY, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced tha
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Wednesday, 25'th Aug 2021
YARDLEY, Pa., Aug. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announce
OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2021 Results - Earnings Call Transcript
03:24pm, Wednesday, 11'th Aug 2021
OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2021 Results - Earnings Call Transcript
OptiNose (OPTN) Reports Q2 Loss, Tops Revenue Estimates
11:00am, Wednesday, 11'th Aug 2021
OptiNose (OPTN) delivered earnings and revenue surprises of -2.33% and 5.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
OptiNose: Q2 Earnings Insights
07:12am, Wednesday, 11'th Aug 2021
Shares of OptiNose (NASDAQ:OPTN) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 21.43% year over year to ($0.44), which missed the estimate of
Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
07:00am, Wednesday, 11'th Aug 2021
Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020
Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
08:00am, Friday, 30'th Jul 2021
Company Expects Top-Line Results in First Quarter 2022
OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
04:05pm, Tuesday, 27'th Jul 2021
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
